Annovis Bio Inc (ANVS) Directors and Executive Officers - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Annovis Bio Inc   (NYSE: ANVS)

Annovis Bio Inc

Officers & Directors


Executives:

- Maria Maccecchini - President and Chief Executive Officer
- Henry Hagopian - Chief Financial Officer (Principal)

Directors:

- Michael Hoffman - Chairman of the Board and Director
- Mark White - Director
- Reid McCarthy - Director
- Claudine Bruck - Director ,

Annovis Bio Inc currently has 8 employees.

  News about Annovis Bio Inc Key Personnel

Annovis Bio Secures FDA Nod for Pivotal Alzheimers Study Amid Financial Turbulence, Signals Hope for Neurodegenerative Disease Advancement,

Annovis Bio Inc. Poised for Breakthroughs in Alzheimer s Treatment as FDA Accepts Phase 3 Study Protocol Amidst Financial ChallengesIn a significant development for the biotechnology sector, Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company focused on combating neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), has announced that the U.S. Food and Drug Administration (FDA) has accepted its updated protocol for a pivotal Phase 3 study aimed at Alzheimer’s disease. Slated to commence in January 2025, this study represents a critical step in the development pathway for Annovis’s innovative therapies.The acceptance by the FDA marks a wate...

Annovis Bio Advances Alzheimer’s Research with FDA Endorsement and Upcoming Presentations at CTAD 2024

In the ongoing race to unlock effective treatments for neurodegenerative disorders, particularly Alzheimer’s disease (AD), Annovis Bio Inc. (NYSE: ANVS) is making notable strides that reflect the increased investment in and urgency surrounding Alzheimer’s research. With the approaching Clinical Trials on Alzheimer s Disease (CTAD) conference set to take place from October 29 to November 1, 2024, in Madrid, Spain, Annovis is poised to showcase its advancements related to its investigational drug, buntanetap.The company recently announced its plan to present two scientific posters detailing fresh findings that highlight the potential of buntanetap as an innovative therapeutic option for early-stage AD pati...

Annovis Bio Adds Four Executives to Leadership Team; Aims to Overcome Financial Challenges and Boost ROI.

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
Annovis Bio Inc., a late-stage clinical drug platform company specializing in transformative therapies for neurodegenerative disorders such as Alzheimer s Disease (AD) and Parkinson s Disease (PD), is pleased to announce the addition of four accomplished professionals to its executive team. Despite recording a cumulative net loss of $48 million during the 12 months ending in the first quarter of 2024, resulting in a negative return on investment (ROI) of -524.18%, the company remains optimistic about its future prospects. However, it is worth noting that within the Healthcare sector, there are 577 other companies that have a higher r...






ANVS Management Effectiveness ANVS Revenue per Employee ANVS Income per Employee


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.